Evolus, Inc.
EOLS
$0.02
Change (1 day)
$17.82
Year High
$9.80
Year Low
Categories
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Earnings for Evolus, Inc. (EOLS)
Earnings in 2023 (TTM): $-61,509,000
According to Evolus, Inc.'s latest financial reports the company's current earnings (TTM) are $-61,509,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Evolus, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-61,509,000 | $-61,685,000 |
| 2022 | $-74,317,000 | $-74,412,000 |
| 2021 | $-46,768,000 | $-46,810,000 |
| 2020 | $-162,936,000 | $-163,013,000 |
| 2019 | $-105,061,000 | $-90,034,000 |
| 2018 | $-46,802,000 | $-46,867,000 |
| 2017 | $-11,731,000 | $-4,480,000 |
| 2016 | $-19,972,000 | $-20,065,000 |
| 2015 | $-31,019,000 | $-31,112,000 |